Unknown

Dataset Information

0

Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report.


ABSTRACT: Salivary gland tumors (SGTs) are heterogeneous tumors that range from benign masses to aggressive high-grade carcinomas with distant metastatic potential and limited response to chemotherapy. Mucoepidermoid carcinoma (MEC) accounts for 10% of SGTs and has a poor prognosis. In this research report, we describe two cases of metastatic high-grade MECs with prolonged response to immune checkpoint inhibitor pembrolizumab. Case 1 presented with a left neck mass, and biopsy of the parotid mass revealed MEC. The patient underwent surgical resection and adjuvant chemoradiation therapy for stage IVB disease. Post-treatment, she was found to have brain and spinal metastases and was placed on pembrolizumab. Case 2 presented with a left neck mass, and biopsy of the right parotid gland revealed MEC. Further staging demonstrated metastatic disease in the lungs, and he was placed on pembrolizumab. Both cases of MEC demonstrated prolonged extracranial responses to pembrolizumab. Although both cases reported little to no PD-L1 expression, these results demonstrate immunotherapy efficacy in advanced/metastatic MEC.

SUBMITTER: Pharaon RR 

PROVIDER: S-EPMC9059780 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report.

Pharaon Rebecca R RR   Gernon Thomas T   Chang Sue S   Vora Nayana N   Villaflor Victoria M VM   Bell Diana D   Afkhami Michelle M   Amini Arya A   Sampath Sagus S   Kang Robert R   Maghami Ellie G EG   Massarelli Erminia E  

Cold Spring Harbor molecular case studies 20220428 3


Salivary gland tumors (SGTs) are heterogeneous tumors that range from benign masses to aggressive high-grade carcinomas with distant metastatic potential and limited response to chemotherapy. Mucoepidermoid carcinoma (MEC) accounts for 10% of SGTs and has a poor prognosis. In this research report, we describe two cases of metastatic high-grade MECs with prolonged response to immune checkpoint inhibitor pembrolizumab. Case 1 presented with a left neck mass, and biopsy of the parotid mass revealed  ...[more]

Similar Datasets

| S-EPMC8647187 | biostudies-literature
| S-EPMC5182193 | biostudies-literature
| S-EPMC9646301 | biostudies-literature
| S-EPMC9840991 | biostudies-literature
| S-EPMC4694941 | biostudies-literature
| S-EPMC5818080 | biostudies-literature
| S-EPMC7648036 | biostudies-literature
| S-EPMC9702244 | biostudies-literature
| S-EPMC7725583 | biostudies-literature
| S-EPMC11002479 | biostudies-literature